A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
Qianwen Guo,Xue Li,Wenbin Li,Rong Wang,Anpeng Zhao,Zihan Wang
DOI: https://doi.org/10.2147/DDDT.S390975
2023-01-15
Abstract:Qianwen Guo, 1, 2, &ast Xue Li, 1, &ast Wenbin Li, 1 Rong Wang, 1 Anpeng Zhao, 1 Zihan Wang 1, 2 1 Pharmacy of the 940th Hospital of PLA Joint Logistics Support Force, Lanzhou, People's Republic of China; 2 School of Pharmacy, Gansu University of Traditional Chinese Medicine, Lanzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenbin Li, Key Laboratory of the Plateau of the Environmental Damage Control, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, 730050, People's Republic of China, Tel +86-931 8994654, Fax +86-931 2662722, Email ; Purpose: To investigate roxadustat's preventive effects on hypoxia damage in the quick ascent to high altitude. Methods: The roxadustat (7.8 mg/kg, 15.6 mg/kg, and 31.2 mg/kg) and control groups of BALB/C mice were distributed at random. To evaluate roxadustat's anti-hypoxic effectiveness at the recommended dose, an atmospheric pressure closed hypoxic experiment was used. Wistar rats were randomly assigned to groups that received normal oxygen, hypoxic, acetazolamide, or roxadustat in order to evaluate the protective effects against hypoxic damage. Animal blood was obtained for arterial blood-gas analysis, inflammatory factors, and the identification of oxidative stress indicators. Animal tissues were removed for pathological investigation. Results: In each group, the mice's survival time was noticeably extended compared to the normal oxygen group. The medium dose had the best time extension rate at 19.05%. Blood SatO 2 and PaO 2 were significantly higher in the roxadustat group compared to the hypoxic group. Erythrocyte content, hemoglobin content, and hematocrit were also significantly higher. Plasma levels of IL-6, TNF-α, and IFN-γ were also significantly lower in the roxadustat group. Roxadustat can also improve the level of oxidative stress in the tissues of hypoxic rats. According to the results of HE staining, roxadustat could greatly lessen the harm done to rat heart, brain, lung, liver, and kidney tissue as a result of hypoxia. Conclusion: Roxadustat can greatly reduce inflammation, oxidative stress, and tissue damage brought on by hypoxia, showing that it can significantly enhance the body's ability to adapt to high altitude exposure. Keywords: roxadustat, high altitude, hypoxia, pharmacodynamics, erythrocyte Hypoxia damages erythrocytes, vascular endothelial cells, and other tissues, such as the lung, brain, and myocardial. High-altitude cerebral edema (HACE) or high-altitude pulmonary edema (HAPE), which can be fatal, may occur from this. These conditions are brought on by an accumulation of reactive oxygen species (ROS), the production of inflammatory mediators, and damage to erythrocytes. 1 The Phase III clinical trial for roxadustat, an inhibitor of the hypoxia-inducible factor-proline hydroxylase (HIF-PHI) used to treat renal anemia, was completed in China on December 18, 2018. Roxadustat was authorized. 2 Proline hydroxylase (PHD) is the rate-limiting enzyme for the decomposition of hypoxia-inducible factor (HIF), a regulator of erythropoietin (EPO). EPO promotes the erythropoiesis process. 3 Roxadustat stabilizes HIF protein expression to encourage the expression of EPO by reducing the rate at which PHD degrades HIF. 4,5 Hemoglobin, which is abundant in erythrocytes and is essential for oxygen combination, consumption, transit, and release, is present in high concentrations. 6 By encouraging EPO production and raising erythrocyte and hemoglobin content, roxadustat can ameliorate hypoxemia and alleviate hypoxia in hypoxic circumstances. The pharmacodynamics of roxadustat were initially investigated through atmospheric pressure closed hypoxic and acute altitude field hypoxia experiments. In the current study, we conducted a randomized controlled experimental study based on the experimental animals to evaluate, the anti-hypoxia effect of roxadustat. This study was approved by the Scientific Research Management Ethics Committee of the 940th Hospital of the Joint Logistic Support Force of the People's Liberation Army (Approval No. 2022KYLL155). All animal work was approved by the Animal Care and Treatment Committee of the 940th Hospital of the Joint Logistic Support Force of the People's Liberation Army (Lanzhou, China). In the use of laboratory animals and research adhere to the 3R principle (Replacement, Reduction, and Refinement), optimize the design of good experiments, standardize the feeding environment and way to ensure the reliability, accuracy and scientific natu -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal